The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

tolerx.com

Founded Year

2000

About Tolerx

Tolerx is a biotechnology company that specializes in biotechnology, cancer treatment, diabetes treatment, autoimmune disease, antibody treatment, and immunotherapy. It is based in Cambridge, Massachusetts.

Tolerx Headquarter Location

300 Technology Square 3rd Floor

Cambridge, Massachusetts, 02139,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tolerx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tolerx is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Tolerx Patents

Tolerx has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/13/2006

5/24/2011

Clusters of differentiation, Immunology, Immune system, Transcription factors, Autoimmune diseases

Grant

Application Date

7/13/2006

Grant Date

5/24/2011

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Autoimmune diseases

Status

Grant

Latest Tolerx News

Tolerx Shutters, Courtagen Gets $8M, OvaScience Emerges, & More Boston-Area Life Sciences News

Oct 14, 2011

XconomyBoston —  We saw stories about New England life sciences companies in a range of stages this week: kicking off, shutting down, and growing. —Cambridge, MA-based biotech Tolerx will be shutting down its operations , after raising a total of more than $150 million from backers like HealthCare Ventures, Skyline Ventures, and Sprout Group. The company’s diabetes drug otelixizumab missed its goals in a pivotal clinical trial earlier this year. Tolerx will be handing the drug over to its partner GlaxoSmithKline and has already begun liquidating its assets through auctions. —My colleague Arlene took a closer look at Cambridge-based Agios Pharmaceuticals, which just added another $20 million on top of the $130 million already committed in a collaboration deal it had in place with New Jersey-based Celgene (NASDAQ: CELG ). The two companies are working to develop cancer metabolism drugs that starve tumors of the enzymes needed to grow. —Courtagen Life Sciences, formerly called Avantra Biosciences, raised $8 million in new funding .The developer of protein biomarkers for disease detection raised a $7 million round of financing last year. —Boston-based OvaScience came out of stealth mode, unveiling its technique (licensed from Harvard Medical School and Massachusetts General Hospital) for improving in vitro fertilization . The company, co-founded and funded by Sirtris Pharmaceuticals veterans Michelle Dipp and Christoph Westphal, aims to improve the quality of eggs using a type of stem cell found in ovaries.

  • When was Tolerx founded?

    Tolerx was founded in 2000.

  • Where is Tolerx's headquarters?

    Tolerx's headquarters is located at 300 Technology Square, Cambridge.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.